Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.
Irbesartan was granted FDA approval on 30 September 1997.
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.
- Associated Conditions
- Diabetic Nephropathy, Hypertension
AMISH : Aprovel for Management of Isolated Systolic Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 436
- Registration Number
- NCT00264212
- Locations
- 🇹🇭
Sanofi-Aventis, Bangkok, Thailand
Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2007-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT00263003
- Locations
- 🇨🇳
Sanofi-Aventis, Taipei, Taiwan
Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)
- Conditions
- Atrial FibrillationCardiovascular Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 9016
- Registration Number
- NCT00249795
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension and Permanent Pacemakers
- Conditions
- Atrial FibrillationHypertension
- First Posted Date
- 2005-09-26
- Last Posted Date
- 2005-11-23
- Lead Sponsor
- Connolly, Stuart, M.D.
- Target Recruit Count
- 200
- Registration Number
- NCT00225667
- Locations
- 🇨🇦
Population Health Research Institute of McMaster University, Hamilton, Ontario, Canada
Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.
- Conditions
- Healthy Subjects
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Technische Universität Dresden
- Registration Number
- NCT00180024
- Locations
- 🇩🇪
Institute of Clinical Pharmacology, Medical Faculty, University of Technology, Dresden, Germany
The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2005-09-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 20
- Registration Number
- NCT00185055
VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis
- Conditions
- Hypertension
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 86
- Registration Number
- NCT00171080
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.
- Conditions
- Healthy Subjects
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2006-09-28
- Lead Sponsor
- Technische Universität Dresden
- Registration Number
- NCT00154024
- Locations
- 🇩🇪
Institute of Clinical Pharmacology, Medical Faculty, University of Technology, Dresden, Germany
Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With Hypercholesterolemia
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 80
- Registration Number
- NCT00152698
- Locations
- 🇩🇪
CRC, Medizinsiche Klinik 4, Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Bavaria, Germany
Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- University of Southern Denmark
- Target Recruit Count
- 200
- Registration Number
- NCT00125645
- Locations
- 🇩🇰
Kardiologisk Klinik, Centralsygehuset Esbjerg/Varde, Esbjerg, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.